Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (24)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Aigner, A.
Right arrow Articles by Zugmaier, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aigner, A.
Right arrow Articles by Zugmaier, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1525-1529, 2003
© 2003 European Society for Medical Oncology

Original Paper

Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients

A. Aigner1,+, P. Brachmann2, J. Beyer2, R. Jäger2, D. Raulais3, M. Vigny3, A. Neubauer2, A. Heidenreich4, S. Weinknecht5, F. Czubayko1 and G. Zugmaier2

1 Department of Pharmacology and Toxicology, 2 Department of Hematology/Oncology and 4 Department of Urology, Philipps University School of Medicine, Marburg, Germany; 3 Institut National de la Santé et de la Recherche Médicale, Paris, France; 5 Department of Urology, Hospital Am Urban, Berlin, Germany

Received 9 January 2003; revised 11 June 2003; accepted 17 July 2003

Background:

Malignant tumors of the testis are among the most common cancers in men between the ages of 15 and 30 years. The sensitivity of detection of known tumor markers depends upon the tumor histology and stage. In other cancers, increased serum concentrations of various angiogenic growth factors have been described as potential markers for tumor progression and metastasis. One main histological feature of testicular cancer is profound angiogenesis.

Design:

In this study, we investigated by sensitive enzyme-linked immunosorbent assays (ELISAs) the levels of various growth and angiogenesis factors in the serum of testicular cancer patients as compared with normal control subjects. For the most profoundly increased growth factors, pleiotrophin (PTN) and fibroblast growth factor-2 (FGF-2), we furthermore analyzed tumor lysates by northern blotting, RT–PCR and ELISA.

Results:

We demonstrate a marked elevation of average serum levels of PTN (~20-fold) and of FGF-2 (~7-fold) in patients and expression of both growth factors in tumor biopsies. To a lesser extent, vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) serum levels were increased, whereas FGF-4 and transforming growth factor-ß levels were similar to those in normal control subjects. Elevation of PTN, FGF-2, EGF and VEGF was detected in seminomatous as well as non-seminatous tumors, and even in early stages.

Conclusions:

PTN and FGF-2 may represent promising new diagnostic markers for testicular cancer with high sensitivity even in early-stage testicular cancer. Further studies are warranted to extend our analyses.

Key words: enzyme-linked immunosorbent assay, fibroblast growth factor-2, growth factor serum levels, pleiotrophin, testicular cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
W. Castillo-Avila, J. M. Piulats, X. Garcia del Muro, A. Vidal, E. Condom, O. Casanovas, J. Mora, J. R. Germa, G. Capella, A. Villanueva, et al.
Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors
Clin. Cancer Res., May 15, 2009; 15(10): 3384 - 3395.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Hatziapostolou, C. Polytarchou, P. Katsoris, J. Courty, and E. Papadimitriou
Heparin Affin Regulatory Peptide/Pleiotrophin Mediates Fibroblast Growth Factor 2 Stimulatory Effects on Human Prostate Cancer Cells
J. Biol. Chem., October 27, 2006; 281(43): 32217 - 32226.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Li, Y. Hu, Y. Huo, M. Liu, D. Freeman, J. Gao, X. Liu, D.-C. Wu, and H. Wu
PTEN Deletion Leads to Up-regulation of a Secreted Growth Factor Pleiotrophin
J. Biol. Chem., April 21, 2006; 281(16): 10663 - 10668.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Boerboom, L. D. White, S. Dalle, J. Courty, and J. S. Richards
Dominant-Stable {beta}-Catenin Expression Causes Cell Fate Alterations and Wnt Signaling Antagonist Expression in a Murine Granulosa Cell Tumor Model
Cancer Res., February 15, 2006; 66(4): 1964 - 1973.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Pariser, G. Herradon, L. Ezquerra, P. Perez-Pinera, and T. F. Deuel
Pleiotrophin regulates serine phosphorylation and the cellular distribution of {beta}-adducin through activation of protein kinase C
PNAS, August 30, 2005; 102(35): 12407 - 12412.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Ferrero
Serum and plasma vascular endothelial growth factor levels in testicular cancer patients
Ann. Onc., June 1, 2004; 15(6): 989 - 990.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.